Azitra Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
13
- Stock Symbol
-
AZTR
- Share Price
-
$0.61
- (As of Friday Closing)
Azitra General Information
Description
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
Contact Information
Website
www.azitrainc.comCorporate Office
- 21 Business Park Drive
- Branford, CT 06405
- United States
Corporate Office
- 21 Business Park Drive
- Branford, CT 06405
- United States
Azitra Stock Performance
As of 13-Nov-2026, Azitra’s stock price is $0.61. Its current market cap is $3.69M with 6.06M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.61 | $0.67 | $0.52 - $3.91 | $3.69M | 6.06M | 2.98M | -$2.80 |
Azitra Financials Summary
As of 30-Jun-2026, Azitra has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (6,991) | 1,942 | (3,372) | 7,687 |
| Revenue | 0 | 0 | 8 | 686 |
| EBITDA | (11,906) | (10,557) | (8,621) | (10,675) |
| Net Income | (12,273) | (10,955) | (8,967) | (11,284) |
| Total Assets | 8,916 | 5,025 | 7,359 | 5,115 |
| Total Debt | 410 | 422 | 556 | 886 |
Azitra Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Azitra Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Azitra Comparisons
Industry
Financing
Details
Azitra Competitors (17)
One of Azitra’s 17 competitors is PellePharm, a Venture Capital-Backed company based in Palo Alto, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| PellePharm | Venture Capital-Backed | Palo Alto, CA | ||||
| Aclaris Therapeutics | Formerly VC-backed | Wayne, PA | ||||
| Quoin Pharmaceuticals | Formerly VC-backed | Ashburn, VA | ||||
| MatriSys Bioscience | Venture Capital-Backed | San Diego, CA | ||||
| S-Biomedic | Formerly VC-backed | Ghent, Belgium |
Azitra Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Azitra Patents
Azitra Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024216162-A1 | Methods and compositions for treating skin disease with recombinant microorganisms | Pending | 02-Feb-2023 | ||
| EP-4658758-A1 | Methods and compositions for treating skin disease with recombinant microorganisms | Pending | 02-Feb-2023 | ||
| WO-2024163886-A1 | Methods and compositions for treating skin disease with recombinant microorganisms | Inactive | 02-Feb-2023 | ||
| AU-2023215360-A1 | Expression of the human lekti gene from the chromosome of staphylococcus epidermidis | Pending | 01-Feb-2022 | ||
| EP-4473087-A1 | Expression of the human lekti gene from the chromosome of staphylococcus epidermidis | Pending | 01-Feb-2022 | C07K14/8135 |
Azitra Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Azitra ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
40.88 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Azitra FAQs
-
When was Azitra founded?
Azitra was founded in 2014.
-
Where is Azitra headquartered?
Azitra is headquartered in Branford, CT.
-
What is the size of Azitra?
Azitra has 13 total employees.
-
What industry is Azitra in?
Azitra’s primary industry is Drug Discovery.
-
Is Azitra a private or public company?
Azitra is a Public company.
-
What is Azitra’s stock symbol?
The ticker symbol for Azitra is AZTR.
-
What is the current stock price of Azitra?
As of 13-Nov-2026 the stock price of Azitra is $0.61.
-
What is the current market cap of Azitra?
The current market capitalization of Azitra is $3.69M.
-
Who are Azitra’s competitors?
PellePharm, Aclaris Therapeutics, Quoin Pharmaceuticals, MatriSys Bioscience, and S-Biomedic are some of the 17 competitors of Azitra.
-
What is Azitra’s annual earnings per share (EPS)?
Azitra’s EPS for 12 months was -$2.80.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
